Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Cardiovascular Drugs
Erschienen in: American Journal of Cardiovascular Drugs 1/2012

01.02.2012 | Adis Drug Evaluation

Rivaroxaban

A Review of its Use for the Prophylaxis of Venous Thromboembolism after Total Hip or Knee Replacement Surgery

verfasst von: Sean T. Duggan

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Rivaroxaban (Xarelto®), an oral oxazolidinone-based anticoagulant, is a potent, selective, direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery.
In large, clinical trials, oral rivaroxaban 10mg once daily was more effective than subcutaneous enoxaparin 40mg once daily in preventing postoperative VTE in patients undergoing THR or TKR surgery. Rivaroxaban was associated with significantly lower incidences of the primary endpoint, total VTE (composite of deep vein thrombosis, non-fatal pulmonary embolism, or death from any cause) compared with enoxaparin regimens across all studies. For example, in the largest trial in patients undergoing THR, total VTE occurred in 1.1% of rivaroxaban recipients and 3.7% of enoxaparin recipients (absolute risk reduction 2.6% [95% CI 1.5, 3.7]) in the modified intent-to-treat population.
Notably, the greater efficacy of rivaroxaban was achieved without a significant increase in the incidence of major bleeding episodes compared with enoxaparin; bleeding events were the most frequently reported adverse events across clinical trials. Pyrexia, vomiting, nausea, and constipation were the most frequently reported of the non-bleeding treatment-emergent adverse events in rivaroxaban recipients and occurred at a similar rate to that with enoxaparin treatment.
In addition, preliminary pharmacoeconomic analyses in Canada and the US indicate that rivaroxaban is a cost-saving treatment strategy versus enoxaparin.
Although the position of rivaroxaban relative to other therapies remains to be fully determined, it is an effective option for the prophylaxis of VTE following THR and TKR.
Literatur
1.
Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163 (7): 759–68.PubMedCrossRef
2.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 381–453S.CrossRef
3.
Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011 Feb. 86 (2): 217–20.PubMedCrossRef
4.
Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 Suppl 1: 17–25.PubMedCrossRef
5.
Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (1): 1–7.PubMed
6.
Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manage Care Pharm 2007 Jul-2007 31. 13 (6): 475–86.
7.
Eriksson BI, Quinlan DJ, Weitz JI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48 (1): 1–22.PubMedCrossRef
8.
Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66(11): 1411–29.PubMedCrossRef
9.
Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005 Mar. 3 (3): 514–21.PubMedCrossRef
10.
Depasse F, Busson J, Mnich J, et al. Effect of BAY 59–7939: a novel, oral direct factor Xa inhibitor on clot-bound factor Xa activity in vitro [abstract no. P1104]. J Thromb Haemost 2005; 3 (Suppl. 1).
11.
Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007 Jul. 33 (5): 515–23.PubMedCrossRef
12.
Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-ox-azolidin-5-yl methyl) thiophene-2-carboxamide (BAY 59–7939): an oral, direct factor Xa inhibitor. J Med Chem 2005 Sep 22. 48 (19): 5900–8.PubMedCrossRef
13.
14.
Perzborn E, Lange U. Rivaroxaban: an oral, direct factor Xa inhibitor inhibits tissue factor-mediated platelet aggregation [abstract no. P-W-642]. J Thromb Haemost 2007; 5 (Suppl. 2).
15.
Wong PC, Crain E, Watson C, et al. Comparative antithrombotic and antihemostatic effects of the direct factor Xa inhibitors, apixaban and rivaroxaban, and the direct thrombin inhibitors, dabigatran and lepirudin, in rabbit models of venous thrombosis and bleeding time [abstract no. 3025]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA).
16.
Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005 Oct. 78 (4): 412–21.PubMedCrossRef
17.
Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 — an oral, direct factor Xa inhibitor — after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005 Dec. 61 (12): 873–80.PubMedCrossRef
18.
Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct factor xa inhibitor — in healthy subjects. Int J Clin Pharmacol Ther 2007 Jun. 45 (6): 335–44.PubMed
19.
Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008 Sep. 100 (3): 453–61.PubMed
20.
Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct factor Xa inhibitor — in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47 (3): 203–16.PubMedCrossRef
21.
Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007 Nov. 47 (11): 1398–407.PubMedCrossRef
22.
Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [letter]. J Thromb Haemost 2007 Apr. 5 (4): 886–8.PubMedCrossRef
23.
Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban — an oral, direct factor Xa inhibitor — has potential for the management of patients with heparininduced thrombocytopenia. Br J Haematol 2008 Jul 30. 143: 92–9.PubMedCrossRef
24.
Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59–7939) — an oral, direct factor Xa inhibitor — has no clinically relevant interaction with napro-xen. Br J Clin Pharmacol 2007 Apr. 63 (4): 469–76.PubMedCrossRef
25.
Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban — an oral, direct factor Xa inhibitor — are not affected by aspirin. J Clin Pharmacol 2006 Sep. 46 (9): 981–90.PubMedCrossRef
26.
Kubitza D, Becka M, Mueck W, et al. Co-administration of rivaroxaban — a novel, oral, direct factor Xa inhibitor — and clopidogrel in healthy subjects [abstract no. 1272]. Eur Heart J 2007 Sep; 28 (Abstr. Suppl.): 189.
27.
Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31 (1): 67–77.PubMedCrossRef
28.
Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban — an oral, direct factor Xa inhibitor — in elderly Chinese subjects. Thromb Haemost 2010; 103 (1): 234–41.PubMedCrossRef
29.
Zhao X, Sun P, Zhou Y, et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol 2009; 68 (1): 77–88.PubMedCrossRef
30.
Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 2007 Feb. 47 (2): 218–26.PubMedCrossRef
31.
Kubitza D, Becka M, Zuehlsdorf M, et al. Effects of single-dose BAY 59–7939 -an oral, direct factor Xa inhibitor — in subjects with extreme body weight [abstract no. 1872]. Blood 2005 Nov 16; 106 (11): 532.
32.
Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010 Nov. 70 (5): 703–12.PubMedCrossRef
33.
Kubitza D, Becka M, Mueck W, et al. The effect of age and gender on the pharmacology and safety of the oral, direct factor Xa inhibitor rivaroxaban [abstract no. P-T-628]. 21st Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva.
34.
Kubitza D, Becka M, Mueck W, et al. The effect of extreme age, and gender on the pharmacology and tolerability of rivaroxaban: an oral, direct factor Xa inhibitor. Blood 2006; 108 (11): 271–2.
35.
36.
37.
38.
Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 May. 46 (5): 549–58.PubMedCrossRef
39.
Moore TK, Plotinov AN, Thyssen A, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011. Epub.
40.
Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5. 37 (5): 1046–55.PubMedCrossRef
41.
Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5. 37 (5): 1056–64.PubMedCrossRef
42.
Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006 Jan. 4 (1): 121–8.PubMedCrossRef
43.
Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 2006 Nov 28. 114 (22): 2374–81.PubMedCrossRef
44.
Turpie AG, Fisher WD, Bauer KA, et al. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005 Nov. 3 (11): 2479–86.CrossRef
45.
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26. 358 (26): 2765–75.PubMedCrossRef
46.
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26. 358 (26): 2776–86.PubMedCrossRef
47.
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lancet 2009 May 16. 373 (9676): 1673–80.PubMedCrossRef
48.
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372(9632): 31–9.PubMedCrossRef
49.
Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009 May. 91 (5): 636–44.PubMedCrossRef
50.
Eriksson BI, Turpie AG, Lassen MR, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effects of specified co-medications [abstract no. 1986]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6–9; San Fransisco (CA).
51.
Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost 2011 Mar. 105 (3): 444–53.PubMedCrossRef
52.
Diamantopoulos A, Lees M, Wells PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010 Oct. 104 (4): 760–70.PubMedCrossRef
53.
Duran A, Sengupta N, Diamantopoulos A, et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payers perspective. J Med Econ 2011; 14(6): 824–34.PubMedCrossRef
54.
Nicolaides AN, Fareed J, Kakkar AK. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006 Jun. 25 (2): 101–61.
55.
Wells PS, Borah BJ, Sengupta N, et al. Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care 2010 Nov; 16(11): 857–863.PubMed
56.
Qadan M, Polk HC Jr, Hohmann SF, et al. A reassessment of needs and practice patterns in pharmacologic prophylaxis of venous thromboembolism following elective major surgery. Ann Surg 2011 Feb. 253 (2): 215–20.PubMedCrossRef
57.
Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64 (14): 1575–96.PubMedCrossRef
58.
Mori S, Matsuura A, Rama Prasad YV, et al. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm Bull 2004 Mar. 27 (3): 418–21.PubMedCrossRef
59.
Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010 Jan. 29 (1): 92–104.PubMedCrossRef
60.
61.
62.
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. [Published erratum appears in Lancet 2007 Dec 15; 370 (9604): 2004]. Lancet 2007 Sep 15. 370 (9591): 949–56.CrossRef
63.
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis & Haemostasis 2007 Nov. 5 (11): 2178–85.
64.
RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 Jan. 24 (1): 1–9.PubMedCrossRef
65.
Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008 Mar. 28 (3): 380–6.PubMedCrossRef
66.
Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68 (5): 691–710.PubMedCrossRef
67.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011. Epub.
68.
Fareed J, Ma Q, Florian M, et al. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004 Feb; 30 Suppl 1: 89–104.PubMed
69.
Diamantopoulos A, LeReun C, Rasul F, et al. Indirect comparisons of rivaroxaban vs alternative prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement [abstract no. 1292]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6–9; San Fransisco (CA).
70.
Lereun C, Wells P, Diamantopoulos A, et al. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ 2011; 14 (2): 238–44.PubMedCrossRef
71.
Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011 Feb. 36 (1): 111–24.PubMedCrossRef
72.
Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010 Apr 15. 51 (2): 113–23.PubMedCrossRef
73.
Bayer. Xarelto regulatory post-marketing surveillance [ClinicalTrials.gov identifier NCT01029743]. US National Institutes of Health, Clinical Trials, gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2012 Jan 11].
Metadaten
Titel
Rivaroxaban
A Review of its Use for the Prophylaxis of Venous Thromboembolism after Total Hip or Knee Replacement Surgery
verfasst von
Sean T. Duggan
Publikationsdatum
01.02.2012
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 1/2012
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/11208470-000000000-00000

Weitere Artikel der Ausgabe 1/2012

American Journal of Cardiovascular Drugs 1/2012 Zur Ausgabe

Review Article

Managing Arrhythmias before and after Aortic Valve Surgery in Children

Review Article

Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus

Original Research Article

Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension

Current Opinion

Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes

Adis Drug Clinical Q&A

Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise